Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · GE HealthCare (GEHC)

GE HealthCare appoints Kevin Lobo to Board; two directors will not stand for re-election

Neutral Impact 3 of 5 leadership Written later

GE HealthCare appointed Kevin A. Lobo, Chair and CEO of Stryker Corporation, as a director effective March 13, 2026, and named him to the Talent, Culture, and Compensation Committee. Directors Risa Lavizzo-Mourey and Tomislav Mihaljevic told the Board they will not stand for re-election at the 2026 Annual Meeting of Stockholders due to other commitments, and the filing says their decisions did not stem from any disagreement with the Company.

Key points

  • Kevin A. Lobo appointed director effective March 13, 2026; term expires at the 2026 Annual Meeting of Stockholders
  • Lobo also appointed to the Talent, Culture, and Compensation Committee, effective immediately
  • Risa Lavizzo-Mourey and Tomislav Mihaljevic will not stand for re-election at the 2026 Annual Meeting
  • Lobo is Chair and CEO of Stryker Corporation and will receive non-employee director compensation under the existing program

The filing

CompanyGE HealthCare (GEHC)
Form8-K, current report
Filed with the SECMar 17, 2026, 9:14 AM ET
Accession number0001932393-26-000013

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:30 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 17, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.